Drug intelligence / Profile preview

drospirenone + metionac

Development stage
Unknown
Lead developer
Margan Biotech
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination drug** containing **drospirenone**, a synthetic progestin, and **Metionac**, a combination product that includes **S-adenosylmethionine** (SAMe), **N-acetylcysteine** (NAC), **alpha-lipoic acid**, and **vitamin B6**. Drospirenone acts as a **progestin**, providing antiandrogenic and antimineralocorticoid effects, and is widely used for contraception, treatment of symptoms related to polycystic ovary syndrome (PCOS), and other hormonal imbalances. Metionac, as a supplement combination, is aimed at modulating **metabolic and endocrine parameters**, potentially offering antioxidant, hepatoprotective, and metabolic support. The drospirenone + metionac combination has been clinically studied for use in **PCOS** in women, in a regimen where oral contraceptive drospirenone is co-administered with Metionac[3]. This combination leverages drospirenone’s hormonal regulation on ovulation and androgen signals, while Metionac is presumed to support metabolic health and oxidative balance, particularly for patients with PCOS who often experience metabolic dysfunction. The **mechanism of action** for drospirenone involves **progesterone receptor agonism**, **mineralocorticoid receptor antagonism**, and **androgen receptor antagonism**[2][4]. Metionac’s action is based on the biological properties of its ingredients: SAMe as a methyl donor and mood modulator, NAC as a glutathione precursor and antioxidant, alpha-lipoic acid as an antioxidant and metabolic cofactor, and vitamin B6 as a key enzyme cofactor in metabolism.

02

Targets

AR (Adrenergic receptors)PR (Progesterone receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on drospirenone + metionac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on drospirenone + metionac.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call